| Basics |
Verastem, Inc.
Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.
|
| IPO Date: |
February 1, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$780.31M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.17 | 3.39%
|
| Avg Daily Range (30 D): |
$0.29 | 3.26%
|
| Avg Daily Range (90 D): |
$0.29 | 3.45%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.2M |
| Avg Daily Volume (30 D): |
2.21M |
| Avg Daily Volume (90 D): |
2.26M |
| Trade Size |
| Avg Trade Size (Sh.): |
251 |
| Avg Trade Size (Sh.) (30 D): |
118 |
| Avg Trade Size (Sh.) (90 D): |
121 |
| Institutional Trades |
| Total Inst.Trades: |
739 |
| Avg Inst. Trade: |
$1.69M |
| Avg Inst. Trade (30 D): |
$1.3M |
| Avg Inst. Trade (90 D): |
$1.27M |
| Avg Inst. Trade Volume: |
.13M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.88M |
| Avg Closing Trade (30 D): |
$1.32M |
| Avg Closing Trade (90 D): |
$1.26M |
| Avg Closing Volume: |
122.41K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-4.28
|
$-1.35
|
$-.39
|
|
Diluted EPS
|
$-4.48
|
$-1.35
|
$-.62
|
|
Revenue
|
$ 13.38M
|
$ 11.24M
|
$ 2.14M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -241.11M
|
$ -98.52M
|
$ -25.93M
|
|
Operating Income / Loss
|
$ -160.24M
|
$ -40.72M
|
$ -43.76M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 24.53M
|
$ 48.89M
|
$ M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 01, 2023:
1:12
|
|
|
|
